. 2021 Oct 22;12:203–213. doi: 10.1016/j.bioactmat.2021.10.018

Table 1.

FDA approved RNA-NP therapies.

Company, drug name	Disease target	Mechanism of action	NP carrier components	RNA	Method, frequency of administration	Year approved by the FDA
Company, drug name	Disease target	Mechanism of action		RNA	Method, frequency of administration	Year approved by the FDA
Alnylam Pharmaceuticals Inc., Onpattro®	Polyneuropathy associated with hereditary transthyretin-mediated amyloidosis	Gene silencing of transthyretin	Lipid NP (DLin-MC3-DMA, DSPC, cholesterol, PEG2000-C-DMG)	siRNA targeting transthyretin	IV infusion, every three weeks	2018
Moderna Therapeutics Inc., Spikevax®	COVID-19	Induces antibody production against SARS-CoV-2	Lipid NP (cholesterol, SM-102, PEG2000-DMG, DSPC)	Synthetic mRNA-1273, encoding stabilized prefusion SARS-CoV-2 spike protein	IM (deltoid), two doses	2020 Emergency use authorization
Pfizer-BioNTech, Comirnaty®	COVID-19	Induces antibody production against SARS-CoV-2	Lipid NP (cholesterol, PEG2000, ALC-0315, DSPC)	Nucleoside modified mRNA BNT162b2, encoding SARS-CoV-2 spike protein	IM (deltoid), two doses	2021

Legend: NP- nanoparticle, DSPC- 1,2-distearoyl-sn-glycero-3-phosphocholine, PEG-polyethylene glycol, IV-intravenous, COVID-19- coronavirus disease 2019, SARS-CoV-2- severe acute respiratory syndrome coronavirus 2, SM-102- sphingomyelin 102, IM- intramuscular.